Advanced search
Publication Cover
Cancer Investigation Volume 17, 1999 - Issue 3
Submit an article Journal homepage
27
Views
38
CrossRef citations to date
0
Altmetric
Original Article

Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial

Mark A. Socinski Multidisciplinary Thoracic Oncology Program and Division of Hernatology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
,
Ann Steagall Multidisciplinary Thoracic Oncology Program and Division of Hernatology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
&
Heidi Gillenwater Multidisciplinary Thoracic Oncology Program and Division of Hernatology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Pages 181-188 | Published online: 11 Jun 2009

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Bert H. O'Neil & Mark A. Socinski. (2003) 96-Hour Paclitaxel Infusions: At Least 93 Hours Too Long. Cancer Investigation 21:4, pages 660-662.
Read now
Sibyl E. Anderson, Eileen M. O'Reilly, David P. Kelsen & David H. Ilson. (2003) Phase II Trial of 96-Hour Paclitaxel in Previously Treated Patients with Advanced Esophageal Cancer. Cancer Investigation 21:4, pages 512-516.
Read now

Articles from other publishers (36)

Maarten van Eijk, Jos H. Beijnen & Alwin D.R. Huitema. (2022) Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors. Anti-Cancer Drugs 34:2, pages 281-289.
Crossref
Ming Gu, Su-Yi Li, Xin-En Huang, Yan Lin, Hong-Yan Cheng & Lin Liu. (2012) A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer. Asian Pacific Journal of Cancer Prevention 13:11, pages 5587-5591.
Crossref
Meltem Baykara, Ugur Coskun, Veli Berk, Metin Ozkan, Muhammet Ali Kaplan, Mustafa Benekli, Halit Karaca, Mevlude Inanc, Abdurrahman Isikdogan, Alper Sevinc, Emin Tamer Elkiran, Umut Demirci & Suleyman Buyukberber. (2012) Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention 13:10, pages 5119-5124.
Crossref
Anne S. Tsao. 2008. Lung Cancer. Lung Cancer 315 333 .
T Berghmans, J J Lafitte, J Lecomte, C G Alexopoulos, O Van Cutsem, V Giner, A Efremidis, M C Berchier, T Collon, A P Meert, A Scherpereel, V Ninane, N Leclercq, M Paesmans & J P Sculier. (2007) Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. British Journal of Cancer 96:11, pages 1644-1649.
Crossref
Kiyoshi Mori, Yukari Kamiyama, Tetsuro Kondo, Yasuhiko Kano & Tetsuro Kodama. (2006) Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology 60:2, pages 189-195.
Crossref
Eleni Karapanagiotou & Konstantinos N. Syrigos. 2006. Tumors of the Chest. Tumors of the Chest 305 314 .
Andres ForeroRuby F. MeredithM.B. KhazaeliSui ShenWilliam E. GrizzleDelicia CareyElizabeth BusbyAlbert F. LoBuglioFrancisco Robert. (2005) Phase I Study of 90 Y-CC49 Monoclonal Antibody Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Effect of Chelating Agents and Paclitaxel Co-Administration . Cancer Biotherapy and Radiopharmaceuticals 20:5, pages 467-478.
Crossref
H.L. West, J.J. Crowley, R.B. Vance, W.A. Franklin, R.B. Livingston, S.R. Dakhil, J.K. Giguere, S.E. Rivkin, M. Kraut, K. Chansky & D.R. Gandara. (2005) Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Annals of Oncology 16:7, pages 1076-1080.
Crossref
Zeeshan Butt, Kimberly Webster, Amy R. Eisenstein, Jennifer Beaumont, David Eton, Gregory A. Masters & David Cella. (2005) Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapy–Lung Scale. Hematology/Oncology Clinics of North America 19:2, pages 389-420.
Crossref
Craig C. Earle & Jane C. Weeks. 2009. Outcomes Assessment in Cancer. Outcomes Assessment in Cancer 160 177 .
V Georgoulias, C Kouroussis, A Agelidou, I Boukovinas, P Palamidas, E Stavrinidis, A Polyzos, K Syrigos, M Veslemes, M Toubis, A Ardavanis, E Tselepatiotis & I Vlachonikolis. (2004) Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. British Journal of Cancer 91:3, pages 482-488.
Crossref
Fadlo R. Khuri, Bonnie S. Glisson, Edward S. Kim, Paul Statkevich, Peter F. Thall, Michael L. Meyers, Roy S. Herbst, Reginald F. Munden, Craig Tendler, Yali Zhu, Sandra Bangert, Elizabeth Thompson, Charles Lu, Xue-Mei Wang, Dong M. Shin, Merrill S. Kies, Vali Papadimitrakopoulou, Frank V. Fossella, Paul Kirschmeier, W. Robert Bishop & Waun Ki Hong. (2004) Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors. Clinical Cancer Research 10:9, pages 2968-2976.
Crossref
Benjamin Movsas & Charles Scott. (2004) Quality-of-life trials in lung cancer: past achievements and future challenges. Hematology/Oncology Clinics of North America 18:1, pages 161-186.
Crossref
David G. Pfister, David H. Johnson, Christopher G. Azzoli, William Sause, Thomas J. Smith, Sherman Baker Jr, Jemi Olak, Diane Stover, John R. Strawn, Andrew T. Turrisi & Mark R. Somerfield. (2004) American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003. Journal of Clinical Oncology 22:2, pages 330-353.
Crossref
Elisabeth Quoix & B. Mennecier. 2004. Malignant Tumors of the Lung. Malignant Tumors of the Lung 265 274 .
Vassilis A Georgoulias. (2002) Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 38, pages 61-66.
Crossref
Frank V Fossella, Thomas Lynch & Frances A Shepherd. (2002) Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38, pages 5-12.
Crossref
Mark A. Socinski, Michael J. Schell, Kamal Bakri, Amy Peterman, Ji‐Hyun Lee, Paul Unger, Steven Yates, Stacie Hudgens & Merrill S. Kies. (2002) Second‐line, low‐dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first‐line chemotherapy with carboplatin plus paclitaxel. Cancer 95:6, pages 1265-1273.
Crossref
J.P. Sculier, T. Berghmans, J.J. Lafitte, M. Richez, P. Recloux, O. Van Cutsem, V. Ninane, P. Mommen, M. Paesmans & J. Klastersky. (2002) A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer 37:1, pages 73-77.
Crossref
O. S. Breathnach, V. Kasturi, F. Kaye, L. Herscher, M. S. Georgiadis, M. Edison, B. S. Schuler, P. Pizzella, S. M. Steinberg, K. O’Neil & Bruce E. Johnson. (2002) Phase II Neoadjuvant Trial of Paclitaxel by 96-Hour Continuous Infusion (CIVI) in Combination With Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology 25:3, pages 269-273.
Crossref
Xavier Bonfill Cosp, Consol Serra, Montse Sacristan, Miquel Nogué, Ferran Losa & Jesús Montesinos. (2002) Second-line chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews.
Crossref
H. Müller. (2002) Combined regional and systemic chemotherapy for advanced and inoperable non-small cell lung cancer. European Journal of Surgical Oncology (EJSO) 28:2, pages 165-171.
Crossref
Primo N. Lara, Derick H. M. Lau & David R. Gandara. (2002) Non-small-cell lung cancer progression after first-line chemotherapy. Current Treatment Options in Oncology 3:1, pages 53-58.
Crossref
Maria Rosaria Valerio, Antonio Russo, Mario Adelfio Latteri, Giuseppe Modica, Gaspare Gulotta, Maria Gabriella Armata, Eugenia Bajardi, Giuseppe Cicero, Giovanni Pantuso, Nello Grassi, Giacoma Agosta & Nicola Gebbia. (2001) Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study. Lung Cancer 34, pages 31-35.
Crossref
H. Müller & S. Guadagni. (2001) Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer. European Journal of Surgical Oncology (EJSO) 27:2, pages 190-195.
Crossref
Greg L. Plosker & Miriam Hurst. (2001) Paclitaxel. PharmacoEconomics 19:11, pages 1111-1134.
Crossref
Rosario Vincenzo Iaffaioli, Anna Tortoriello, Adriano Gravina, Gaetano Facchini, Giacinto Turitto, Stefano Elia, Salvatore Griffo, Maria Gentile, Gaetano Fraioli, Adele Frattolillo, Paolo Muto, Michele Libutti, Valeria De Marino, Alfonso Illiano & Alfonso Barbarisi. (2000) Phase I–II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB–IV non-small cell lung cancer. Lung Cancer 30:3, pages 203-210.
Crossref
C. HuismanE.F. SmitG. GiacconeP.E. Postmus. (2000) Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review. Journal of Clinical Oncology 18:21, pages 3722-3730.
Crossref
Stylianos Kakolyris & Vassilis Georgoulias. (2000) The Role of Gemcitabine and Paclitaxel as Second-Line Chemotherapy for the Treatment of Advanced Non–Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer 2:1, pages 43-47.
Crossref
Domenico Ferrigno & Gianfranco Buccheri. (2000) Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?. Lung Cancer 29:2, pages 91-104.
Crossref
Yuh-Min Chen, Reury-Perng Perng, Kuang-Young Yang, Wei-Chun Lin, Hsiao-Wei Wu, Chun-Ming Tsai & Jacqueline Whang-Peng. (2000) Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer 29:2, pages 139-146.
Crossref
Kenneth B. Ain, Merrill J. Egorin & Philip A. DeSimone. (2000) Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion. Thyroid 10:7, pages 587-594.
Crossref
Frank V. FossellaRussell DeVoreRonald N. KerrJeffrey CrawfordRonald R. NataleFrank DunphyLeonard KalmanVincent MillerJin Soo LeeMelvin MooreDavid GandaraDaniel KarpEverett VokesMark KrisYong KimFrancis GamzaLuz Hammershaimb. (2000) Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens. Journal of Clinical Oncology 18:12, pages 2354-2362.
Crossref
Frank V. Fossella. (2000) Second–line chemotherapy for non—small–cell lung cancer. Current Oncology Reports 2:1, pages 96-101.
Crossref
Mark A. Socinski. (1999) Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer. The Oncologist 4:5, pages 408-416.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.